Review: taking Zofran and Zantac together


Summary

Drug interactions are reported among people who take Zofran and Zantac together. This review analyzes the effectiveness and drug interactions between Zofran and Zantac. It is created by eHealthMe based on reports of 128 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Zofran and Zantac >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Zofran

Zofran has active ingredients of ondansetron hydrochloride. It is often used in post procedural nausea. (latest outcomes from Zofran 7 users)

Zantac

Zantac has active ingredients of ranitidine hydrochloride. It is often used in indigestion. (latest outcomes from Zantac 35,003 users)

On Jul, 27, 2016

128 people who take Zofran, Zantac are studied.


Number of reports submitted per year:

Zofran and Zantac drug interactions.

Drug effectiveness over time:

Zofran:
  • < 1 month: 100.0% - (1 of 1 people)
  • 1 - 6 months: 100.0% - (1 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 2 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Zantac:
  • < 1 month: 0.0% - (0 of 1 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 33.0% - (1 of 3 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Zofran:
  • female: 33.0% - (1 of 3 people)
  • male: 100.0% - (1 of 1 people)
Zantac:
  • female: 0.0% - (0 of 3 people)
  • male: 100.0% - (1 of 1 people)

Drug effectiveness by age:

Zofran:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 100.0% - (1 of 1 people)
  • 30-39: 0.0% - (0 of 2 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 100.0% - (1 of 1 people)
Zantac:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 0.0% - (0 of 2 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 100.0% - (1 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • renal failure acute
  • blood bilirubin increased
  • engraftment syndrome
  • oxygen saturation decreased
  • pyrexia
  • cardio-respiratory arrest
  • tachycardia
  • abdominal pain
  • respiratory failure
  • acute respiratory distress syndrome
1 - 6 months:
  • pneumocystis jiroveci pneumonia
  • renal failure acute
  • respiratory failure
  • thrombocytopenic purpura
1 - 2 years:
  • activated partial thromboplastin time prolonged
  • chest discomfort
  • chest pain
  • cough
  • dilatation ventricular
  • electrocardiogram qt corrected interval prolonged
  • hyperhidrosis
  • infection
  • leukocytosis
  • musculoskeletal pain
2 - 5 years:
  • abdominal bloating
  • aphasia - primary progressive
  • apraxia
  • burping
  • confusional state
  • constipation aggravated
  • cyclic vomiting syndrome
  • dysphagia aggravated
  • migraine aggravated
  • tardive dyskinesia
10+ years:
  • abdominal bloating
  • aphasia - primary progressive
  • apraxia
  • burping
  • confusional state
  • constipation aggravated
  • cyclic vomiting syndrome
  • dysphagia aggravated
  • migraine aggravated
  • tardive dyskinesia
not specified:
  • nausea
  • hypotension
  • arthralgia
  • vomiting
  • joint stiffness
  • anaemia
  • pyrexia
  • pain
  • scar
  • urinary tract infection

Most common drug interactions by gender *:

female:
  • arthralgia
  • joint stiffness
  • nausea
  • anaemia
  • hypotension
  • scar
  • nephrogenic systemic fibrosis
  • vomiting
  • multi-organ failure
  • pruritus
male:
  • pyrexia
  • nausea
  • respiratory failure
  • abdominal pain
  • pain
  • vomiting
  • hyperhidrosis
  • oxygen saturation decreased
  • renal failure acute
  • tachycardia

Most common drug interactions by age *:

2-9:
  • abdominal pain
  • acute respiratory distress syndrome
  • blood albumin decreased
  • blood creatinine increased
  • blood magnesium increased
  • bone marrow failure
  • bradycardia
  • brain oedema
  • cardio-respiratory arrest
  • coma
10-19:
  • blood bilirubin increased
  • engraftment syndrome
  • renal failure acute
  • acute graft versus host disease in liver
  • respiratory failure
  • anorexia
  • chest pain
  • chills
  • graft versus host disease
  • pancreatitis acute
20-29:
  • abdominal pain lower
  • abortion missed
  • acute respiratory distress syndrome
  • cerebral artery thrombosis
30-39:
  • anaemia
  • dehydration
  • fanconi syndrome
  • febrile neutropenia
  • haemolytic anaemia
  • abdominal bloating
  • aphasia - primary progressive
  • apraxia
  • burping
  • confusional state
40-49:
  • hypotension
  • nephrogenic systemic fibrosis
  • arthralgia
  • bronchopneumonia
  • dry skin
  • endocardial fibrosis
  • excoriation
  • extremity contracture
  • interstitial lung disease
  • joint contracture
50-59:
  • nausea
  • arteriosclerosis coronary artery
  • anaemia
  • bundle branch block right
  • erythema
  • myocardial infarction
  • anaemia postoperative
  • arterial stenosis
  • arthralgia
  • bone disorder
60+:
  • pyrexia
  • vomiting
  • anaemia
  • nausea
  • neutropenia
  • thrombocytopenia
  • oxygen saturation decreased
  • chest pain
  • dehydration
  • dizziness

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Zofran and Zantac?

Can you answer these questions?

More questions for: Zofran, Zantac

You may be interested in these reviews

More reviews for: Zofran, Zantac

On eHealthMe, Zofran (ondansetron hydrochloride) is often used to treat post procedural nausea. Zantac (ranitidine hydrochloride) is often used to treat indigestion. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.